🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A big thank you to Ilse Aigner, President of the Landtag of Bavaria, for visiting us today in connection with the grant we received last summer for PRS-220!

Great talks at the Respiratory Innovation Summit today, including our Chief Development Officer presenting the @PierisPharma inhaled platform for respiratory disease #ats2022

Thrilled to share our preclinical data poster of PRS-220, our inhaled CTGF inhibitor for #IPF, with the #ats2022 community! Looking forward to bringing this into phase 1 studies this year!

Kicking off #bio2022 in San Diego. Looking forward to a productive week with the @PierisPharma team!

Congratulations to Galina Katzmann for her 20-year Pieris anniversary! Her work has involved purifying Anticalin proteins in the discovery phase, some of which are now in clinical trials. We are thrilled to have her as part of our team, and we are excited for the years to come!

Congratulations to Florian Witte for 5 years at Pieris! Florian’s leadership in heading Alliance Management at Pieris has been crucial to the company as we continue to add and work continuously with our collaboration partners to develop new therapies for patients.

Proud to share that @PierisPharma has initiated clinical development of our anti-CTGF program for IPF, PRS-220. IPF is a terrible disease and we look forward to advancing a therapy that we believe has the potential for meaningful impact on patients. bit.ly/3zBe3nc

We are excited to announce the dosing of the first subject in the phase 1 healthy volunteer study of PRS-220, an inhaled CTGF inhibitor we are developing for #IPF!

Thrilled to share an important clinical alliance milestone within the Pieris 4-1BB franchise: first person dosed by our partner with CD228 x 4-1BB bispecific Mabcalin™ compound! Read the announcement here: tinyurl.com/96tcn4aa

🚀 Exciting news from @PierisPharma! Cinrebafusp alfa shows promising initial results in 2L+ HER2+ gastric cancer at #AACR2023. Excited to see the potential of our Anticalin tech & 4-1BB franchise in transforming cancer treatment! 🧪🔬bit.ly/3KLBgYP

Excited to be part of American Thoracic Society (ATS), showcasing the latest in the @PierisPharma's inhaled pipeline at RIS. Today CDO Shane Olwill presented on PRS-220, our novel inhaled CTFG antagonist in the 'Innovators in Fibrosis' set. Can't wait for more insightful exchanges at #ATS2023.

Great update from @PierisPharma at American Thoracic Society (ATS) today: Our R&D team is presenting at #ATS2023 on PRS-220, our inhaled CTGF program that's outperformed systemic antibody pamrevlumab in a lung fibrosis mouse model. A major leap in localized interventions. #IPF

Following merger w/ Pieris, Palvella Therapeutics is a biopharmaceutical company focused on novel therapies for patients suffering from serious, rare genetic skin diseases w/ no approved therapies. Will trade on @nasdaqexchange - ticker $PVLA. Learn more: bit.ly/3VEProC

Palvella shares are trading on the @nasdaqexchange under the ticker symbol $PVLA. #raredisease #lymphaticmalformations

Following merger w/ Pieris, Palvella Therapeutics is a biopharmaceutical company focused on novel therapies for patients suffering from serious, rare genetic skin diseases w/ no approved therapies. Will trade on @nasdaqexchange - ticker $PVLA. Learn more: bit.ly/3VEProC

We’re pleased that our Phase 2 results from our study of QTORINTM rapamycin in microcystic lymphatic malformations were recently published in the Journal of Vascular Anomalies. Please see our release to learn more bit.ly/4fQLTHg

Expanding our Phase 3 clinical trial to evaluate the safety and efficacy of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of Microcystic Lymphatic Malformations (microcystic LMs) to include children 3-5 years old. $PVLA bit.ly/4jQ586S

May is International Month of Awareness for Vascular Birthmarks, Anomalies, and Syndromes. We're joining the global effort to raise awareness—because with greater understanding comes compassion, advocacy, and progress. Let’s continue moving forward together.

We’re honored to ring the Nasdaq opening bell on May 12—an incredible moment celebrating Palvella’s transition to a publicly traded company. Thank you to our patients, investors, collaborators, advocacy partners, and team! Watch the livestream: bit.ly/4dmEGPL

We were thrilled to have the honor of ringing the Nasdaq opening bell today! 📷 Nasdaq